Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X:
“Efficacy and safety of ASP3082, a novel protein degrader, as monotherapy in patients (patients) with non-small cell lung cancer (NSCLC) with KRAS G12D mutation.
By Alex Spira at Targets25.”
More posts featuring Raffaele Colombo.
